Neuropace Inc. (NPCE) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Neuropace Inc. is a medical device company focused on the RNS System, a brain-responsive neuromodulation system for treating drug-resistant focal epilepsy. The company is classified as an emerging growth company and a smaller reporting company. As of May 8, 2026, there were approximately 34.1 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $22,068 | $22,524 |
| Gross Profit | $18,048 | $17,342 |
| Gross Margin | 81.8% | 77.0% |
| Net Loss | $(6,689) | $(6,589) |
| Diluted Net Loss Per Share | $(0.20) | $(0.21) |
| Cash, Cash Equivalents & Short-Term Investments | $54,000 | $61,100 (Dec 31, 2025) |
| Long-Term Debt (Net) | $59,021 | $58,884 (Dec 31, 2025) |
| Operating Cash Flow | $(5,900) | $(7,482) |
Material Changes vs. Prior Period
- Revenue: Decreased 2% to $22.1 million. The decline was primarily due to the termination of the exclusive distribution agreement with DIXI Medical (which ended September 30, 2025), offset by an increase in RNS System unit sales (initial implants and replacements).
- Gross Margin: Improved to 81.8% from 77.0%. This increase is attributed to the removal of lower-margin DIXI Medical product sales from the revenue mix.
- Operating Expenses: Total operating expenses increased 5% to $23.6 million. Sales and marketing expenses rose 5% due to increased headcount and marketing spend. General and administrative expenses increased 20% primarily due to personnel-related costs. Research and development expenses decreased 3% due to lower clinical trial costs.
- Debt Structure: In June 2025, the company repaid its CRG Term Loan in full using proceeds from a new $60.0 million MidCap Term Loan. Interest expense decreased 29% in Q1 2026 compared to Q1 2025 due to the lower effective interest rate of the new MidCap facility.
Guidance, Outlook, and Risks
- Liquidity: The company holds $54.0 million in cash and short-term investments. Management believes this is sufficient to fund operations for at least the next 12 months. The company is currently in compliance with all financial covenants of the MidCap Credit Agreement, including a minimum liquidity threshold of $60.0 million (until June 2027) and a trailing 12-month revenue requirement of $71.9 million (current trailing revenue is $85.2 million).
- Strategic Shift (DIXI Medical): The company expects to present the operating results of the DIXI Medical distribution agreement as discontinued operations in future periods, likely beginning in Q2 2026, as the wind-down period concludes and remaining inventory is returned.
- Regulatory Outlook: The company filed a Premarket Approval Supplement (PMA-S) in December 2025 to expand the RNS System indication to patients with drug-resistant idiopathic generalized epilepsy, based on data from the NAUTILUS study. Approval is anticipated in mid-2026. Pediatric label expansion efforts (ages 12-17) are ongoing.
- Risks: Key risks include reliance on a single product (RNS System), dependence on single-source suppliers, potential delays in FDA approvals for label expansion, and the need to achieve cash flow breakeven without DIXI revenue. The company also faces risks related to cybersecurity, data privacy, and potential changes in healthcare reimbursement policies.
Investor Verification Checklist
- Verify the timeline and criteria for the presentation of DIXI Medical results as discontinued operations in Q2 2026 filings.
- Monitor the status of the PMA-S submission for idiopathic generalized epilepsy and the anticipated mid-2026 approval date.
- Review the company's ability to maintain the $60.0 million liquidity covenant under the MidCap Credit Agreement given the burn rate of approximately $5.9 million per quarter.
- Assess the impact of the DIXI agreement termination on long-term revenue growth projections and the path to cash flow breakeven.
- Confirm the status of the NAUTILUS study two-year data collection and its potential impact on future regulatory submissions.